Search Orphan Drug Designations and Approvals
-
Generic Name: | 5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid |
---|---|
Date Designated: | 06/08/2022 |
Orphan Designation: | Treatment of primary hyperoxaluria type 1 |
Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
Date Designation Withdrawn or Revoked: | 05/31/2024 |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
BioMarin Pharmaceutical Inc. 105 Digital Drive Novato, California 94949 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-